S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY

Patent №

US 6,020,139

Granted

2000-02-01

Filed 1995

Owner

ORIDIGM CORPORATION

+1 more

Lab

AI components

1

planning

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

08428963

A new paradigm of disease centers around the metabolic pathways of S-adenosyl-L-methionine (SAM), the intermediates of these pathways and other metabolic pathways influenced by the SAM pathways. Methods are provided to analyze and modulate SAM pathways associated with a disease or condition. Such methods permit identification and utilization of diagnostic and therapeutic protocols and agents for such disease states and conditions.

PlanningA61K 31/7076A61K 31/198A61K 31/4188A61K 31/455A61K 38/1709A61K 45/06

AI classification

Planning0.56
Natural language0.03
Machine learning0.02
Evolutionary computation0.01
Knowledge representation0.00
AI hardware0.00
Vision0.00
Speech0.00

Ownership

ORIDIGM CORPORATION

assignment · 75250214

MEDIQUEST THERAPEUTICS, INC.

namechg · 144990213

Assignors

SCHWARTZ, DENNIS E., VERMEULEN, NICOLAAS M.J., O'DAY, CHRISTINE L.

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC